Neuroendokrine Tumoren
| Autor: | H Scherübl, F Raue, K Frank-Raue |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pathology
medicine.medical_specialty medicine.diagnostic_test business.industry Medullary thyroid cancer Context (language use) Magnetic resonance imaging Neuroendocrine tumors medicine.disease 030218 nuclear medicine & medical imaging Functional imaging Pheochromocytoma 03 medical and health sciences 0302 clinical medicine Somatostatin Pituitary adenoma 030220 oncology & carcinogenesis medicine Radiology Nuclear Medicine and imaging business |
| Zdroj: | Der Radiologe. 59:952-960 |
| ISSN: | 1432-2102 0033-832X |
| DOI: | 10.1007/s00117-019-0574-x |
| Popis: | Context Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms found in all organs. They often present with characteristic clinical syndromes due to hormone hypersecretion. Diagnostics In addition to hormone diagnostics molecular-genetic work-up can play an important role. Imaging Morphological imaging comprises ultrasound, endoscopy, computed tomography (CT) and magnetic resonance imaging (MRI) scans. Functional imaging of NET relies on radioligands that bind to specific receptors or transporters (Ga-68-DOTATATE-PET-CT, Tc-99-tektrotyd-SPECT/CT, F‑18-DOPA-PET/CT). Therapy Somatostatin analogs either native or coupled to radionuclides are potent drugs for treating various neuroendocrine tumors. Conclusion The requirements of imaging are determined by clinical presentation, laboratory findings, tumor stage, the presence of a tumor syndrome and the need of a personalized systemic treatment modality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink